Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 208

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 8
Chunk 208
---
semia, partially offset by lower process development expenses. The increase in our indirect expenses was primarily due to an increase in compensation and related expenses, driven principally by workforce-related expenses.

Other Income and ExpenseThree Months Ended September 30,Nine Months Ended September 30,(In thousands)2025202420252024Gain on sale of contingent payments$— $889,136 $— $889,136 Milestone payment from gain on sale of oncology business— 200,000 — 200,000 Interest income, net13,369 13,059 43,969 30,068 Other income, net67 1,651 1,843 4,864 

Other Income and Expense - Three Months Ended September 30, 2025 vs. Three Months Ended September 30, 2024 –  The decrease in gain on sale of contingent payments was due to the sale of the Vorasidenib Royalty Rights in the three months ended September 30, 2024 discussed above in Overview. The decrease in milestone payment from gain on sale of oncology business was due to the receipt of the Vorasidenib Milestone Payment in the three months ended September 30, 2024 discussed above in Overview. 

Other Income and Expense - Nine Months Ended September 30, 2025 vs. Nine Months Ended September 30, 2024 –  The decrease in gain on sale of contingent payments was due to the sale of the Vorasidenib Royalty Rights in the nine months ended September 30, 2024 discussed above in Overview. The decrease in milestone payment from gain on sale of oncology business was due to the receipt of the Vorasidenib Milestone Payment in the nine months ended September 30, 2024 discussed above in Overview. The increase in interest income, net in the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024 was primarily attributable to increased return on our investments. 

27

Net (Loss) IncomeThree Months Ended September 30,Nine Months Ended September 30,(In thousands)2025202420252024Net (loss) income$(103,433)$947,915 $(304,742)$770,248 

Net (Loss) Income - Three Months Ended September 30, 2025 vs. Three Months Ended September 30, 2024 – The increase in net loss for the three